Literature DB >> 12324577

A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.

Shigeki Umemura1, Yoshihiko Segawa, Keiichi Fujiwara, Ichiro Takata, Nobuhiko Seki, Yoshiyuki Tokuda, Kenji Eguchi, Koichi Mandai.   

Abstract

We describe a case of recurrent metastatic thymoma showing an excellent response to salvage paclitaxel monotherapy. The patient had undergone a series of platinum-based chemotherapy treatments during the previous 20-month period and the patient's disease was considered resistant to such therapy at the start of treatment with paclitaxel. This is the first report to suggest that paclitaxel has anti-thymoma activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12324577     DOI: 10.1093/jjco/hyf059

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.

Authors:  Girum L Lemma; Ju-Whei Lee; Seena C Aisner; Corey J Langer; William J Tester; David H Johnson; Patrick J Loehrer
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

2.  Metastatic thymoma presenting as spontaneous epidural lumbar haematoma.

Authors:  Ganeshwaran Shivapathasundram; Vanessa Sammons; Renata Bazina
Journal:  Eur Spine J       Date:  2015-05-27       Impact factor: 3.134

Review 3.  Treatment of advanced thymoma and thymic carcinoma.

Authors:  Arun Rajan; Giuseppe Giaccone
Journal:  Curr Treat Options Oncol       Date:  2009-04-21

4.  Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.

Authors:  Yusuke Okuma; Yukio Hosomi; Kageaki Watanabe; Satoshi Takahashi; Tatsuru Okamura; Tsunekazu Hishima
Journal:  Int J Clin Oncol       Date:  2015-12-08       Impact factor: 3.402

5.  Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.

Authors:  Tracey L Evans
Journal:  Onco Targets Ther       Date:  2012-09-07       Impact factor: 4.147

6.  Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.

Authors:  Yusuke Okuma; Yukio Hosomi; Shingo Miyamoto; Masahiko Shibuya; Tatsuru Okamura; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

Review 7.  [Advances on diagnosis and treatment of malignant thymic tumors].

Authors:  Jinghui Wang; Shucai Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

8.  Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.

Authors:  Somayye Taghvaei; Farzaneh Sabouni; Zarrin Minuchehr
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.